Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Cash Flow Per Share?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Cash Flow Per Share is 
3.69 (1Y +29.1% )

ALXN Stock Price & Cash Flow Per Share

Cash Flow Per Share for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Cash Flow Per Share

chevron_right 2021 3.84 +39.5x *
( +14.7% / year avg)
chevron_left 1995 -0.09
vertical_align_top Peak 3.84 +13.0x *
vertical_align_bottom Bottom -0.32
arrow_drop_up # Up Years 18 18 of 27
years up.
arrow_drop_down # Down Years 9
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -1.08x faster than it's cash flow per share over the same period.
  • If ALXN grows it's stock at the same rate as it's cash flow per share (+14.7%/year) , it's stock price will grow +394% and hit $428.49 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 18 years (0%) it's cash flow per share were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
5-Year Change 🚀
+138%$6.4BNet Revenue (Sales)
+181%$608.8MCost of Revenue (Sales)
+135%$5.8BGross Profit Margin
-1.58%3.62Gross Profit Margin Ratio
+78.1%$1.2BResearch and Development (R&D)
+109%$1.8BSelling, General, and Administrative (SG&A)
+91.1%$3.2BTotal Operating Expenses
+101%$3.8BCost & Expenses
+38.7%$110.8MInterest Expense/Income, Net
+51.0%$300.4MDepreciation & Amortization (D&A)
+191%$2.9BEBITDA
+22.2%1.81EBITDA Margin
+227%$2.6BOperating Income
+37.0%1.63Operating Margin
-25.4%-$114.8MTotal Other Income/Expenses
+323%$2.4BPretax Income (Earnings)
+77.5%1.48Pretax Income (Earnings) Margin
-83.0%$219.2MProvision For Income Taxes
-391.6%$2.1BNet Income (Earnings)
-222.1%1.35Net Profit Margin
-401.9%9.78Earnings Per Share (EPS)
-401.9%9.78Earnings Per Share (EPS) Diluted
-3.15%$876.4MShares Outstanding
-3.15%$876.4MShares Outstanding (Diluted)
+154%$11.9BCash and Cash Equivalents
-88.2%$139.6MShort Term Investments
+105%$12.0BCash And Short-Term Investments
+227%$3.1BInventory
+135%$23.3BTotal Current Assets
+136%$5.8BPP&E
+1.69%$20.4BGoodwill
-37.3%$12.0BIntangible Assets
-17.4%$32.4BGoodwill and Intangible Assets
+37.6%$72.4BTotal Assets
+152%$474.4MAccounts Payables
-18.6%$569.6MShort-term Debt
+6,334%$1.1BOther Current Liabilities
+111%$6.5BTotal Current Liabilities
-27.2%$9.7BLong-term Debt
+291%$6.5BDeferred Tax Liabilities Non-Current
+147%$2.4BOther Non-Current Liabilities
+16.8%$19.3BTotal Non-Current Liabilities
+31.7%$25.8BTotal Liabilities
+370%$21.0BRetained Earnings
-331.5%-$500.0MAccumulated Other Comprehensive Income Loss
+41.2%$46.6BTotal Shareholders Equity
+37.6%$72.4BTotal Liabilities & Stockholders Equity
-26.8%$10.2BTotal Debt
-117.2%-$1.6BNet Debt
-128.0%-$436.8MDeferred Income Tax
+67.5%$342.0MStock-Based Compensation (SBC)
-1,029.8%$1.9BChange in Working Capital
+144%$176.4MAccounts Receivables
+145%$16.8BOther Working Capital
-154.3%-$67.2MOther Non-Cash Items
+276%$3.4BNet Cash Provided by Operating Activities
+1.9%-$310.0MInvestments in PP&E
-97.1%-$22.4MPurchase of Investments
-96.5%$10.0MSales/Maturities of Investments
-58.7%-$322.4MNet Cash used for Investing Activities
-16.7%-$306.0MCommon Stock Repurchased
-98.9%-$4.8MOther Financing Activities
-60.1%-$295.2MNet Cash Used Provided by Financing Activities
-1,272.3%$80.0MEffect of Exchange Rate Changes on Cash
-544.5%$2.8BNet Change in Cash
+160%$12.1BCash at End of Period
+76.1%$9.3BCash at Beginning of Period
+276%$3.4BOperating Cash Flow
+1.9%-$310.0MCapital Expenditure (capex)
+418%$3.1BFree Cash Flow
  • ALXN Historical Cash Flow Per Share Table

    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Cash Flow Per Share YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 3.84 26.3% - -
    4/1/2020 3.04 64.7% - -
    4/1/2019 1.85 174.0% - -
    4/1/2018 0.67 -47.6% - -
    4/1/2017 1.28 43.7% - -
    4/1/2016 0.89 -3.5% - -
    4/1/2015 0.93 29.4% - -
    4/1/2014 0.72 42.0% - -
    4/1/2013 0.5 -3.8% - -
    4/1/2012 0.52 66.4% - -
    4/1/2011 0.31 57.5% - -
    4/1/2010 0.2 20.3% - -
    4/1/2009 0.17 24855.1% - -
    4/1/2008 0.0 -100.3% - -
    4/1/2007 -0.25 -20.5% - -
    4/1/2006 -0.32 37.3% - -
    4/1/2005 -0.23 28.6% - -
    4/1/2004 -0.18 -35.4% - -
    4/1/2003 -0.28 30.4% - -
    4/1/2002 -0.22 164.3% - -
    4/1/2001 -0.08 19.0% - -
    4/1/2000 -0.07 12.6% - -
    4/1/1999 -0.06 -20.6% - -
    4/1/1998 -0.08 252.4% - -
    4/1/1997 -0.02 -63.8% - -
    4/1/1996 -0.06 -36.9% - -
    4/1/1995 -0.09 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
  • Cash flow per share = (CFO - Pref.dividends)/(Number of common shares outstanding)
    Operating cash flow on a per share basis

    For more detailed definitions, please see Investopedia.
    Year Cash Flow Per Share YoY % Change Stock Price YoY % Change (Stock Price) operating cash flow shares outstanding non
    4/1/2021 3.84 26.3% 3362.00 876.40
    4/1/2020 3.04 64.7% 2679.50 882.60
    4/1/2019 1.85 174.0% 1651.20 894.50
    4/1/2018 0.67 -47.6% 600.20 890.90
    4/1/2017 1.28 43.7% 1149.39 895.18
    4/1/2016 0.89 -3.5% 803.70 899.49
    4/1/2015 0.93 29.4% 767.80 826.50
    4/1/2014 0.72 42.0% 565.50 790.16
    4/1/2013 0.50 -3.8% 393.43 779.82
    4/1/2012 0.52 66.4% 396.44 753.29
    4/1/2011 0.31 57.5% 230.31 730.12
    4/1/2010 0.20 20.3% 142.34 711.01
    4/1/2009 0.17 24855.1% 112.25 671.94
    4/1/2008 0.00 -100.3% 0.94 604.80
    4/1/2007 -0.25 -20.5% -146.18 573.67
    4/1/2006 -0.32 37.3% -100.94 404.34
    4/1/2005 -0.23 28.6% -108.29 465.94
    4/1/2004 -0.18 -35.4% -70.64 396.30
    4/1/2003 -0.28 30.4% -86.14 305.33
    4/1/2002 -0.22 164.3% -62.52 290.75
    4/1/2001 -0.08 19.0% -23.53 289.18
    4/1/2000 -0.07 12.6% -16.53 239.62
    4/1/1999 -0.06 -20.6% -11.00 180.44
    4/1/1998 -0.08 252.4% -13.10 170.08
    4/1/1997 -0.02 -63.8% -2.40 137.72
    4/1/1996 -0.06 -36.9% -5.60 101.63
    4/1/1995 -0.09 -6.80 71.72